期刊
FRONTIERS IN GENETICS
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2022.1013266
关键词
lysosomal acid lipase; LIPA; Wolman Disease; Cholesteryl Ester Storage Disease; GWAS; smooth muscle cells; atherosclerosis; nonalcoholic fatty liver disease
资金
- Vanier Canada Graduate Scholarship
- Canadian Institutes of Health Research Fellowship Award
- Canadian Institutes of Health Research Project Grant [PJT- 156137]
- Michael Smith Health Research BC/Providence Research Health Professional Investigator Award
This review discusses the role of Lysosomal acid lipase (LAL) in lysosomes and its association with genetic mutations in diseases such as Wolman Disease and cholesteryl ester storage disease. Furthermore, the review explores the potential role of LAL in cardiovascular risk and fatty liver disease. It also emphasizes the need for further research on enhancing LAL activity as a novel treatment strategy for reducing the development and regression of ischemic cardiovascular disease and fatty liver.
Lysosomal acid lipase (LAL), encoded by the gene LIPA, is the sole neutral lipid hydrolase in lysosomes, responsible for cleavage of cholesteryl esters and triglycerides into their component parts. Inherited forms of complete (Wolman Disease, WD) or partial LAL deficiency (cholesteryl ester storage disease, CESD) are fortunately rare. Recently, LAL has been identified as a cardiovascular risk gene in genome-wide association studies, though the directionality of risk conferred remains controversial. It has also been proposed that the low expression and activity of LAL in arterial smooth muscle cells (SMCs) that occurs inherently in nature is a likely determinant of the propensity of SMCs to form the majority of foam cells in atherosclerotic plaque. LAL also likely plays a potential role in fatty liver disease. This review highlights the nature of LAL gene mutations in WD and CESD, the association of LAL with prediction of cardiovascular risk from genome-wide association studies, the importance of relative LAL deficiency in SMC foam cells, and the need to further interrogate the pathophysiological impact and cell type-specific role of enhancing LAL activity as a novel treatment strategy to reduce the development and induce the regression of ischemic cardiovascular disease and fatty liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据